Robert Ely
About Robert Ely
Robert Ely serves as the Senior Director of Process Chemistry and CMC at BridgeBio, where he has worked since 2023. He holds a Ph.D. in Organic Chemistry from Boston College and has extensive experience in the pharmaceutical industry, including roles at Onyx Pharmaceuticals and Achaogen.
Work at BridgeBio
Robert Ely has been employed at BridgeBio since 2021. He currently holds the position of Senior Director, Process Chemistry/CMC. In this role, he is responsible for overseeing the development and optimization of chemical processes for drug substances. His work contributes to the advancement of BridgeBio's portfolio in the biotechnology sector. Ely's tenure at BridgeBio has spanned over three years, during which he has played a key role in various projects aimed at enhancing drug development efficiency.
Education and Expertise
Robert Ely earned his Ph.D. in Organic Chemistry from Boston College, where he studied from 2007 to 2012. Prior to this, he completed his Bachelor of Arts in Chemistry and Biochemistry at the University of Colorado Boulder from 2003 to 2007. His academic background provides a strong foundation for his expertise in process chemistry and drug development, which he has applied throughout his career in various pharmaceutical companies.
Background
Robert Ely began his professional career as a Graduate Research Assistant at Boston College, working from 2007 to 2012. Following his academic tenure, he joined Array BioPharma as a Medicinal Chemist for one year. He then transitioned to Onyx Pharmaceuticals, Inc., where he served as Scientist I from 2012 to 2015. Ely continued to build his career in the pharmaceutical industry with roles at Medivation and Achaogen before joining BridgeBio.
Previous Positions
Before his current role at BridgeBio, Robert Ely held several positions in the pharmaceutical industry. He worked as a Medicinal Chemist at Array BioPharma from 2006 to 2007, followed by a Scientist I role at Onyx Pharmaceuticals from 2012 to 2015. He then served as Scientist II at Medivation from 2016 to 2017 and as Senior Scientist at Achaogen from 2017 to 2018. These positions have contributed to his extensive experience in drug development and process chemistry.